Taurine: A novel tumor marker for enhanced detection of breast cancer among female patients

Angiogenesis

Volumn 14, Issue 3, 2011, Pages 321-330

  El Agouza, I M ^a   Eissa, S S ^b   El Houseini, M M ^b   El Nashar, Dalia E ^c   Abd El Hameed, O M ^d  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY   (Egypt)

^d HIGHER INSTITUTE OF ENGINEERING   (Egypt)

Author keywords

Angiogenesis (VEGF, CD31); Antioxidant taurine; Apoptosis (TNF and Caspas 3)

Indexed keywords

CA 15-3 ANTIGEN; CASPASE 3; CD31 ANTIGEN; TAURINE; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AMINO ACID BLOOD LEVEL; ANGIOGENESIS; APOPTOSIS; ARTICLE; BENIGN TUMOR; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; BREAST CANCER; BREAST CARCINOMA; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EGYPTIAN; ENZYME ACTIVITY; ETHNIC GROUP; FAMILY HISTORY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; TISSUE HOMOGENATE;

ADULT; ANTIGENS, CD31; BREAST NEOPLASMS; CASPASE 3; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; TAURINE; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052744446     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9215-3     Document Type: Article

References (53)

1. S Omar H Khaled R Gaafar R Zekry S Eissa O El-Khatib 2003 Breast cancer in Egypt: a review of disease presentation and detection strategies East Mediterr Health J 9 3 448 463 15751939 1:STN:280:DC%2BD2M7itFCrtA%3D%3D (Pubitemid 40521212)
2. S Boulos M Gadallah S Neguib E Essam A Youssef, et al. 2005 Breast screening in the emerging world: high prevalence of breast cancer in Cairo Breast 14 5 340 346 16131468 10.1016/j.breast.2005.07.002 1:STN:280: DC%2BD2MrktVKmuw%3D%3D (Pubitemid 41510189)
3. J Mobley R Brueggemeier 2004 Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer Carcinogenesis 25 1 3 9 14514655 10.1093/carcin/bgg175 1:CAS:528:DC%2BD2cXnslSi (Pubitemid 38128614)
4. J Lin J Manson J Selhub J Buring S Zhang 2007 Plasma cysteinylgly-cine Llevels and breast cancer risk in women Cancer Res 67 23 11123 11127 18056435 10.1158/0008-5472.CAN-07-3061 1:CAS:528:DC%2BD2sXhtlyiurvF (Pubitemid 350248535)
5. Ries LAG, Eisner MP, Kosary CL, et al. (2002) SEER cancer statistics review, 1973-1999. National Cancer Institute, Bethesda, MD
6. Folkman J (2004) Angiogenesis in breast cancer. In: Bland K, Copland E (eds) The breast "comprehensive management of benign and malignant disorders", vol 1, 3rd edn. Saunders, Missouri, pp 563-586
7. Folkman J, Kalluri R (2006) Tumor angiogenesis. In: Kufe DW, Bast RC, Hart WN, et al. (Holland- Frei Cancer Medicin) (ONLINE 7th edn) by BC Decker Inc Hamilton. Londn 2006. (AACR) www.bcdecker.com/cm7 ), pp 161-194
8. K Heer H Kumar R Read N Fox, et al. 2001 Serum vascular endothelial growth factor in breast cancer its relation with cancer type and estrogen receptor Clin Cancer Res 7 3491 3494 11705867 1:CAS:528:DC%2BD3MXptFais7o%3D (Pubitemid 33069985)
9. W Choi M Lewis D Lawson Q Yin-Goen G Birdsong, et al. 2005 Angiogenic, lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters, VEGF-family gene expression Mod Pathol 18 1 143 152 15297858 10.1038/modpathol.3800253 1:CAS:528:DC%2BD2MXivVSk (Pubitemid 40128107)
10. M Parton I Smith 2001 Studies of apoptosis in breast cancer Cancer Breast BMJ 322 1528 1532 1:CAS:528:DC%2BD3MXls1KqtLw%3D (Pubitemid 32588351)
11. I Hadjiloucas AP Glimor J Bundred H Streuli 2001 Assessment of apoptosis in human breast tissue using an antibody against the active form of caspase -3; relation to tumor histopathologyical charechteristics Br J Cancer 85 10 1522 15260 11720439 10.1054/bjoc.2001.2115 1:CAS:528:DC%2BD38XkslemtA%3D%3D (Pubitemid 34001584)
12. H Yang S Edgareton D Thor 2005 Reconstituation of caspase-3 sensitizes mcf-7 breast cancer cells to radiation Int J Oncol 26 6 1675 1680 15870885 1:CAS:528:DC%2BD2MXkvFyrurs%3D
13. Ames BN (1983) Dietary carcinogens and anticarcinogens; oxygen radicals and degenerative diseases. Science (Washington, DC) 221:1256-1264
14. A Daigeler AM Chromik A Geisler D Bulut C Hilgert A Krieg L Klein-Hitpass M Lehnhardt W Uhl U Mittelkotter 2008 Synergistic apoptotic effects of taurolidine, TRAIL on squamous carcinoma cells of oesophagus Int J Oncol 32 6 1205 1220 18497982 10.3892/ijo-32-6-1205 1:CAS:528:DC%2BD1cXns1agu70%3D
15. A Jacobi C Menenakos C Braumann 2005 Taurolidine a new drug with anti-tumor, anti-angiogenic effects Anticancer Drugs 16 9 917 921 16162968 10.1097/01.cad.0000176502.40810.b0 1:CAS:528:DC%2BD2MXpvFOqt70%3D (Pubitemid 41416082)
16. Y Sadszuka M Matsuura T Snobobe 2009 The effect of taurine, a novel biochemical modulator, on the antitumor activity of Doxorubicin Biol Pharm Bull 32 9 1584 1587 10.1248/bpb.32.1584
17. El Agouza I, Eissa S, Mansure M, El Nashare D (2010) The possiblity of antiangiogenetic effect of Taurine in hepatocellular carcinoma: human and expremental evaluation (in press)
18. El Agouza IM, El Nashar D (2011) Serum taurine as a marker in endometrial carcinoma. Women Health Care. Accepted June 2011
19. GP McMahon R O'Kennedy MT Kelly 1996 High-performance liquid chromatographic determination of ne in human plasma using pre-column extraction and derivatization Pharm Biomed Anal 148 10 1287 1294 10.1016/0731-7085(95) 01697-X (Pubitemid 26235189)
20. Sox HC, Blatt MA, Higgins MC, Marton KI (1988) Medical decision making. Butterworths, Boston, MA
21. M Duffy 2006 Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52 3 345 351 16410341 10.1373/clinchem.2005.059832 1:CAS:528:DC%2BD28Xit1ShtrY%3D
22. R Rodak H Kubota H Ishihara HP Eugster D Konu H Mohler, et al. 2005 Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells, inhibition of the vascular endothelial growth factor production by taurolidine J Neurosurg 102 6 1055 1068 16028765 10.3171/jns.2005.102.6.1055 1:CAS:528:DC%2BD2MXmtVShurs%3D (Pubitemid 43193975)
23. C Bast P Ravdin F Hayes S Bates H Fritsche M Jessup, et al. 2001 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 1865 1878 11251019 (Pubitemid 32230890)
24. J Martinez-Trufero AR de Lobera J Lao T Puertolas A Artal-Cortes, et al. 2005 Serum markers and prognosis in locally advanced breast cancer Tumor 91 6 522 530 (Pubitemid 43251124)
25. M Sorak S Arsenijević G Lukić N Arsenijević P Ristić, et al. 2007 Relations-hip of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma J BUON 12 1 99 104 17436409 1:STN:280:DC%2BD2s3is1Krtg%3D%3D (Pubitemid 46824678)
26. Ragaz J, Miller K, Badve S, et al. (2004) Advers association of expressed vascular endothelial growth factor (VEGF), Her-2, Cox-2, uPA and EMSY with long-term outcome of stage I-III breast cancer. J Clin Oncol 22(Suppl 14S):524
27. P Schneider D Miller 2005 Overview: VEGF and angiogenesis in breast cancer "Angiogenesis, the process of new blood vessel formation, plays a central role in both local tumor growth and distant metastasis in breast cancer" J Clin Oncol 23 1782 1790 15755986 10.1200/JCO.2005.12.017 1:CAS:528:DC%2BD2MXjtVCqu7w%3D (Pubitemid 46211430)
28. G Gasparini M Toi R Miceli, et al. 1999 Clinical relivance of vascular endothelial growth factor and thiamdine phosphorlase in patient with node-positive breast cancer trated with ither adiuvant chemotherapy or hormone therapy Cancer J Sci Am 5 101 111 10198732 1:STN:280:DyaK1M3hsV2ntw%3D%3D (Pubitemid 29169299)
29. B Linderholm K Grankvist N Wilking M Johansson B Tavelin R Henriksson 2000 Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment J Clin Oncol 18 1423 1431 10735889 1:CAS:528: DC%2BD3cXivVeisro%3D (Pubitemid 30205387)
30. JA Foekens HA Peters N Grebenchtchikov, et al. 2001 High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res 61 5407 5414 11454684 1:CAS:528: DC%2BD3MXnsVCru7o%3D (Pubitemid 32694919)
31. E Konecny G Meng M Untch, et al. 2004 Association between Her-2/neu and vascular endothelial rowth factor expression predicts clinical outcome in primary breast patients Clin Cancer Res 10 1706 1716 15014023 10.1158/1078-0432.CCR-0951-3 1:CAS:528:DC%2BD2cXhvFCltrs%3D (Pubitemid 38435562)
32. H Yang S Edgareton D Thor 2005 Reconstituation of caspase-3 sensitizes mcf-7 breast cancer cells to radiation Int J Oncol 26 6 1675 1680 15870885 1:CAS:528:DC%2BD2MXkvFyrurs%3D
33. B Faraglia A Bonsignore F Scaldaferri A Boninsegna A Cittadini 2005 Caspase-3 inhibits the growth of breast cancer cells independent of protease activity J Cell Physiol 202 2 478 482 15316934 10.1002/jcp.20149 1:CAS:528:DC%2BD2MXot1aitg%3D%3D (Pubitemid 40041318)
34. J Van Antwerp J Martin M Verma R Green 1998 Inhibition of TNF-induced apoptosis by NF-kappa B Trends Cell Biol 8 107 111 9695819 10.1016/S0962- 8924(97)01215-4 (Pubitemid 28077734)
35. V Sardisia 1995 Role of antioxidant in health maintenance Natur Clin Pract 10 1 19 25 10.1177/011542659501000119
36. GJ Fuchs 2005 Antioxidants for children with kwashiorkor BMJ 330 1095 1096 15891206 10.1136/bmj.330.7500.1095 (Pubitemid 40686186)
37. Halliwell B, Gutteridge J (2006) Free radicals in biology and medicine, ed 4. Clarendon Press, Oxford, JMC
38. M Percival 1998 Antioxidant Clin Nutr Insights 25 738
39. P Calabresi F Goulette J Darnowski 2001 Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent Cancer Res 61 6816 6821 11559556 1:CAS:528:DC%2BD3MXntFaisb0%3D (Pubitemid 32896506)
40. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattrodt M, Brock M (2002) The effect of taurolidine on brain tumor cells. Anticancer Res 22(2A): 809-814 (Pubitemid 34475233)
41. L Nici B Monfils P Calabresi 2004 The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma Clin Cancer Res 10 7655 7661 15569998 10.1158/1078-0432.CCR-0196-03 1:CAS:528:DC%2BD2cXhtVanurzE (Pubitemid 39557529)
42. I Obrosova A Minchenko V Marinescu, et al. 2001 Antioxidant attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats Diabetologia 44 9 1102 1110 11596663 10.1007/s001250100631 1:CAS:528:DC%2BD3MXmtlWltr8%3D (Pubitemid 32835501)
43. N Maulik D Das 2002 Redox signaling in vascular angiogenesis Free Radic Biol Med 33 1047 1060 12374616 10.1016/S0891-5849(02)01005-5 1:CAS:528:DC%2BD38Xns1Sisbo%3D
44. N Brown R Bicknell 2001 Hypoxia and oxidative stress in breast cancer: oxidative stress-its effects on the growth, metastatic potential and response to therapy of breast cancer Breast Cancer Res 3 323 327 10.1186/bcr315 11597322 10.1186/bcr315 1:CAS:528:DC%2BD3MXntlegsLk%3D (Pubitemid 32851163)
45. N Ilhan N Ilhan 2003 Vascular endothelial growth factor and oxidative damage in cancer Clin Biochem 36 3 225 228 12726933 10.1016/S0009-9120(02)00450- 2 1:CAS:528:DC%2BD3sXjt1Kgs7k%3D (Pubitemid 36515130)
46. B Nespereira M Perez-Ilzarbe P Fermandez A Fuentes, et al. 2003 Vitamin E and C dowenregulat VEGF and VEGFR-2 expression in apolipoprotein-E-deficient Atherosclerosis 17 63 73
47. CB Ambrosone JR Marshall JE Vena R Laughlin S Graham, et al. 1995 Interaction of family history of breast cancer and dietary antioxidants with breast cancer risk Cancer Causes Control 6 407 415 8547538 10.1007/BF00052180 1:STN:280:DyaK28%2FlvVGjtg%3D%3D
48. L Freudenheim R Marshall E Vena R Laughlin R Brasure, et al. 1996 Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients J Natl Cancer Inst 88 340 348 8609642 10.1093/jnci/88.6.340 1:CAS:528:DyaK28Xitlaku74%3D (Pubitemid 26094240)
49. C Abramjuk M Bueschges J Schnorr K Jung A Staack M Lein 2009 Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo Oncol Rep 22 2 409 414 19578784 1:CAS:528:DC%2BD1MXpt12qt7c%3D
50. C Braumann CN Gutt J Scheele C Menenakos W Williams JM Muller CA Jacobi 2009 Taurolidin reduces the tumor stimulating cytokine interleukin-1beta in patients with respectable gastrointestinal cancer: a multicentre prospective randomized trial World J Surg Oncol 7 32 19309495 10.1186/1477-7819-7-32
51. Hoksch B, Rufer B, Gazdhar A, Bilici M, Beshay M, Gugger M, Schmid RA (2009) Taurolidin in the prevention and therapy of lung metastasis. Eur J Cardiothorac Surg 36(6):1058-1063. Epub 2009 Oct 21
52. Aceto N, Bertino P, Barbone D, Tassi G, Manozo L, Porta C, Mutti L, Guadino G (2009) Taurilidine and Oxidative stress: a rationale for local treatment of methothelioma. Eur Respir J. 34(6):1399-1407. Epub 200 May 21
53. S Srivastava R Roy S Siggh P Kumar D Alela SN Sankhwar A Goel AA Sonkar 2010 Taurine-apossible fingerprint biomarker in non-muscle invasive bladder cancer: a pilot study by 1H NMR spectroscopy Cancer Biomarker 6 1 11 20